Answers are grounded in this paper and cite their sources.
Delayed implant-based reconstruction after conventional mastectomy is constrained by scar adherence and a poorly compliant skin and soft-tissue envelope. Whether a definitive implant can be placed in one delayed operation without reopening the mastectomy scar or tissue expansion remains unclear. Delayed endoscopic direct-to-implant breast reconstruction through a single axillary incision (DEDTI-BR) combines concealed access, endoscopic scar release, vascularized retropectoral coverage, and structured postoperative envelope adaptation. We retrospectively reviewed 50 consecutive patients who underwent DEDTI-BR from March 2025 to April 2026; follow-up was updated on August 2, 2026. Primary outcomes were any 90-day complication, Clavien-Dindo grade II or higher complication, unplanned reoperation, and implant loss. All 50 patients completed ≥ 90-day follow-up. Secondary outcomes included BREAST-Q scores, PMRT- and concurrent-procedure-stratified analyses, and descriptive cumulative sum (CUSUM) analysis of 21 standalone cases. All 50 procedures were completed as planned without conversion to open surgery; 29 included concurrent procedures, and 26 patients (52.0%) had received PMRT. Any 90-day complication occurred in 4 patients (8.0%; 95% CI, 3.2%-18.8%), and grade II or higher complications occurred in 3 (6.0%; 95% CI, 2.1%-16.2%). No unplanned reoperation or implant loss occurred within 90 days. All 50 patients completed the 3-month BREAST-Q assessment. Satisfaction with breasts increased from 50.8 ± 5.6 to 75.4 ± 7.4, psychosocial well-being from 58.0 ± 4.9 to 71.3 ± 5.8, and physical well-being of the chest from 77.9 ± 3.9 to 80.9 ± 5.8 (all P < 0.001). No statistically significant 3-month BREAST-Q differences were observed by PMRT status. Operative time declined across the standalone-case sequence, the CUSUM curve peaked at case 7 and returned toward the stable zone around case 13 in the DEDTI-BR-alone group. DEDTI-BR provides a one-stage delayed direct-to-implant pathway through concealed axillary access, without reopening the mastectomy scar or prior tissue expansion. In this consecutive series, the integrated strategy achieved low early morbidity, no 90-day implant loss, and substantial gains in patient-reported outcomes. These findings support DEDTI-BR as a reconstructive option for selected postmastectomy patients. Not applicable.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: